Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Tiratricol** is an orally administered small-molecule thyroid hormone analogue and endogenous triiodothyronine metabolite. It is a thyroid hormone receptor agonist that can enter cells independently of monocarboxylate transporter 8, allowing thyroid hormone signaling to be restored in tissues affected by MCT8 deficiency while reducing the elevated circulating thyroid hormone burden responsible for peripheral thyrotoxicosis. Tiratricol is marketed as **Emcitate** for peripheral thyrotoxicosis associated with monocarboxylate transporter 8 deficiency, also known as Allan-Herndon-Dudley syndrome. ([ema.europa.eu](https://www.ema.europa.eu/en/documents/product-information/emcitate-epar-product-information_en.pdf))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tiratricol.